Cargando…

Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From “Omics” Research

While the modern therapeutic armamentarium to treat multiple myeloma (MM) patients allows a longer control of the disease, this second-most-frequent hematologic cancer is still uncurable in the vast majority of cases. Since MM plasma cells are subjected to various types of chronic cellular stress an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manni, Sabrina, Fregnani, Anna, Barilà, Gregorio, Zambello, Renato, Semenzato, Gianpietro, Piazza, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243738/ https://www.ncbi.nlm.nih.gov/pubmed/32500036 http://dx.doi.org/10.3389/fonc.2020.00802

Ejemplares similares

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
por: Zambello, Renato, et al.
Publicado: (2020)

Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma
por: Carrino, Marilena, et al.
Publicado: (2019)

Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
por: Barilà, Gregorio, et al.
Publicado: (2021)

Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia
por: Teramo, Antonella, et al.
Publicado: (2020)

Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
por: Manni, Sabrina, et al.
Publicado: (2021)

CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma
por: Fregnani, Anna, et al.
Publicado: (2022)

Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?
por: Zambello, Renato, et al.
Publicado: (2014)

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma
por: Canovas Nunes, Sara, et al.
Publicado: (2018)

Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis
por: Barilà, Gregorio, et al.
Publicado: (2020)

The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients
por: Bacci, Christian, et al.
Publicado: (2021)

Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance
por: Manni, Sabrina, et al.
Publicado: (2018)

Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?
por: Giussani, Edoardo, et al.
Publicado: (2021)

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways
por: Manni, Sabrina, et al.
Publicado: (2017)

A bone-based 3D scaffold as an in-vitro model of microenvironment–DLBCL lymphoma cell interaction
por: Ceccato, Jessica, et al.
Publicado: (2022)

Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options
por: Calabretto, Giulia, et al.
Publicado: (2021)

Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
por: Piazza, Francesco, et al.
Publicado: (2010)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2022)

Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation
por: Barilà, Gregorio, et al.
Publicado: (2018)

Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder Really Two Distinct Diseases?
por: Zambello, Renato, et al.
Publicado: (2014)

Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia
por: Mariotti, Barbara, et al.
Publicado: (2020)

P1279: INHIBITION OF PROTEIN KINASE CK2 AND BCL-2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH
por: Manni, S., et al.
Publicado: (2022)

Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI
por: Zambello, Renato, et al.
Publicado: (2018)

Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells
por: Manni, Sabrina, et al.
Publicado: (2013)

Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
por: Manni, Sabrina, et al.
Publicado: (2022)

A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells
por: Gasparini, Vanessa Rebecca, et al.
Publicado: (2020)

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
por: Quotti Tubi, Laura, et al.
Publicado: (2013)

LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don’t Make an Evidence
por: Calabretto, Giulia, et al.
Publicado: (2022)

Experts’ consensus on the definition and management of high risk multiple myeloma
por: Marcon, Chiara, et al.
Publicado: (2023)

Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma
por: Zhuang, Yan, et al.
Publicado: (2023)

STAT3 mutation impacts biological and clinical features of T-LGL leukemia
por: Teramo, Antonella, et al.
Publicado: (2017)

Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation
por: Teramo, Antonella, et al.
Publicado: (2022)

Omics Insights into Animal Resilience and Stress Factors
por: Basile, Federica, et al.
Publicado: (2020)

Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia
por: Bhattacharya, Dipabarna, et al.
Publicado: (2022)

Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
por: Piazza, Francesco, et al.
Publicado: (2022)

Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies
por: Cinetto, Francesco, et al.
Publicado: (2021)

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
por: Romano, Alessandra, et al.
Publicado: (2021)

Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
por: Manni, Sabrina, et al.
Publicado: (2017)

Correction to: Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
por: Manni, Sabrina, et al.
Publicado: (2018)

Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
por: Spinello, Zaira, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4dn322mif6se0p93nv64nr2q89